News coverage about Bio Blast Pharma (NASDAQ:ORPN) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bio Blast Pharma earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.584277078778 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Bioblast Pharma Ltd (ORPN) Moves 1.79% - Evergreen Caller (evergreencaller.com)
- Needle Action Activity Spotted in Bioblast Pharma Ltd (ORPN) - Financial News Review (finnewsreview.com)
- Investor Brief: Watching the Signals on Shares of Bio Blast Pharma Ltd (ORPN) - Wall Street Review (thewallstreetreview.com)
- Should Farsighted Investors Pay Attention to Bioblast Pharma Ltd. (NASDAQ:ORPN)? - FLBC News (flbcnews.com)
Shares of Bio Blast Pharma (NASDAQ:ORPN) remained flat at $0.57 during midday trading on Monday. The stock had a trading volume of 20,877 shares. Bio Blast Pharma has a 12-month low of $0.41 and a 12-month high of $2.04. The stock’s market capitalization is $9.34 million. The firm has a 50 day moving average of $0.63 and a 200 day moving average of $0.71.
ORPN has been the topic of a number of research analyst reports. S&P Equity Research boosted their price target on Bio Blast Pharma from $0.56 to $0.63 in a research note on Friday, April 28th. ValuEngine lowered Bio Blast Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
COPYRIGHT VIOLATION NOTICE: This story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://stocknewstimes.com/2017/08/21/bio-blast-pharma-orpn-earning-somewhat-favorable-press-coverage-study-finds.html.
About Bio Blast Pharma
Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease.
Receive News & Ratings for Bio Blast Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio Blast Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
